Indacaterol er en én gang dagligt inhaleret β 2-agonist til behandling af kronisk obstruktiv lungesygdom

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Indacaterol er en én gang dagligt inhaleret β 2-agonist til behandling af kronisk obstruktiv lungesygdom. / Ulrik, Charlotte Suppli.

I: Ugeskrift for Laeger, Bind 172, Nr. 47, 22.11.2010, s. 3260-3.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Ulrik, CS 2010, 'Indacaterol er en én gang dagligt inhaleret β 2-agonist til behandling af kronisk obstruktiv lungesygdom', Ugeskrift for Laeger, bind 172, nr. 47, s. 3260-3.

APA

Ulrik, C. S. (2010). Indacaterol er en én gang dagligt inhaleret β 2-agonist til behandling af kronisk obstruktiv lungesygdom. Ugeskrift for Laeger, 172(47), 3260-3.

Vancouver

Ulrik CS. Indacaterol er en én gang dagligt inhaleret β 2-agonist til behandling af kronisk obstruktiv lungesygdom. Ugeskrift for Laeger. 2010 nov. 22;172(47):3260-3.

Author

Ulrik, Charlotte Suppli. / Indacaterol er en én gang dagligt inhaleret β 2-agonist til behandling af kronisk obstruktiv lungesygdom. I: Ugeskrift for Laeger. 2010 ; Bind 172, Nr. 47. s. 3260-3.

Bibtex

@article{426b15fd3e7e4c10b8d8d8385ce96389,
title = "Indacaterol er en {\'e}n gang dagligt inhaleret β 2-agonist til behandling af kronisk obstruktiv lungesygdom",
abstract = "The aim of pharmacological treatment of COPD is best possible disease control. Bronchodilators are accepted as the mainstay of COPD therapy. This short review focuses on the available data on indacaterol - a new once-daily beta2-agonist. The analysed studies show that indacaterol has clinically important effects on quality of life, dyspnoea, level of FEV1, hyperinflation, and exacerbation rate in patients with COPD. Indacaterol is therefore in the near future expected to be an important part of maintenance therapy for patients with COPD.",
author = "Ulrik, {Charlotte Suppli}",
year = "2010",
month = nov,
day = "22",
language = "Dansk",
volume = "172",
pages = "3260--3",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "47",

}

RIS

TY - JOUR

T1 - Indacaterol er en én gang dagligt inhaleret β 2-agonist til behandling af kronisk obstruktiv lungesygdom

AU - Ulrik, Charlotte Suppli

PY - 2010/11/22

Y1 - 2010/11/22

N2 - The aim of pharmacological treatment of COPD is best possible disease control. Bronchodilators are accepted as the mainstay of COPD therapy. This short review focuses on the available data on indacaterol - a new once-daily beta2-agonist. The analysed studies show that indacaterol has clinically important effects on quality of life, dyspnoea, level of FEV1, hyperinflation, and exacerbation rate in patients with COPD. Indacaterol is therefore in the near future expected to be an important part of maintenance therapy for patients with COPD.

AB - The aim of pharmacological treatment of COPD is best possible disease control. Bronchodilators are accepted as the mainstay of COPD therapy. This short review focuses on the available data on indacaterol - a new once-daily beta2-agonist. The analysed studies show that indacaterol has clinically important effects on quality of life, dyspnoea, level of FEV1, hyperinflation, and exacerbation rate in patients with COPD. Indacaterol is therefore in the near future expected to be an important part of maintenance therapy for patients with COPD.

M3 - Tidsskriftartikel

VL - 172

SP - 3260

EP - 3263

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 47

ER -

ID: 40201733